Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038077 · ClinicalTrials.gov registry record · Phase 3
Reversal of Ventricular Remodeling With Toprol-XL
A Phase 3 study of Heart Failure, Congestive, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT00038077: Completed Phase 3 study of Heart Failure, Congestive, sponsored by AstraZeneca.
NCT00038077 is a Phase 3 study of Heart Failure, Congestive that has completed, run by AstraZeneca. The registered enrollment target is 300 participants, below the 667-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038077, a Phase 3 study of Heart Failure, Congestive, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Seloken ZOK/Toprol-XL
Study Locations (20)
California
- - Los Angeles
- - Northridge
- - Redondo Beach
- - Riverside
Florida
- - Clearwater
- - Melbourne
- - Vero Beach
Alabama
- - Birmingham
- - Mobile
Indiana
- - Indianapolis
- - Jeffersonville
Louisiana
- - New Orleans
- - Shreveport
Maryland
- - Baltimore
- - Salisbury
Arkansas
- - Little Rock
Connecticut
- Research Site - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2001-08 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
What the finished NCT00038077 record still lists
NCT00038077 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 667-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00038077 names 20 study sites across 11 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00038077 about?
NCT00038077 is a clinical study titled "Reversal of Ventricular Remodeling With Toprol-XL". The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.
What is the current status of trial NCT00038077?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2001-08. Estimated completion is 2003-09.
What conditions does trial NCT00038077 study?
This clinical trial studies the following conditions: Heart Failure, Congestive.
What interventions are being tested in trial NCT00038077?
The interventions under investigation include: Placebo (DRUG), Seloken ZOK/Toprol-XL (DRUG).
Who is sponsoring clinical trial NCT00038077?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00038077 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Congestive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00038077's enrollment target sits among peer trials
300 16th of 39 higher than 24 of 39 other Heart Failure, Congestive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure, Congestive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
COMPLETED · Phase 3
-
Occluded Artery Trial (OAT)
COMPLETED · Phase 3
-
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
COMPLETED · Phase 3
-
PIE II: Pharmacological Intervention in the Elderly II
COMPLETED · Phase 3
-
Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
COMPLETED · Phase 3
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia